{
  "docId": "019de070-dce8-70ee-8639-85282f075771",
  "docSlug": "622e4280fc41e900213786c9a95190a7",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 40,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Slide 32 of a presentation, likely from AstraZeneca given the drug names.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-dce8-70ee-8639-85282f075771/32",
  "deckHref": "/decks/019de070-dce8-70ee-8639-85282f075771",
  "deckJsonHref": "/decks/019de070-dce8-70ee-8639-85282f075771.json",
  "deckAnchorHref": "/decks/019de070-dce8-70ee-8639-85282f075771#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.33,
        "x": 0.67,
        "y": 0.82
      },
      "kind": "callout",
      "text": "Multiple Phase III trials underway",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6747856f-ea3a-4458-ac9d-48577f70b546",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.33,
        "x": 0.35,
        "y": 0.82
      },
      "kind": "callout",
      "text": "AZD5305 now in Phase I trials",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a15bfdba-487d-478d-b548-22b4a0d082f7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.33,
        "x": 0.03,
        "y": 0.82
      },
      "kind": "callout",
      "text": "First PARPi to demonstrate benefit in BRCAm adjuvant breast cancer",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2869f8e-c34c-4122-bad8-9cba6ab7e841",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.22,
        "x": 0.41,
        "y": 0.58
      },
      "kind": "chart",
      "text": "Relative Tumour Volume vs Days of Treatment showing combination activity",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84c252ad-7871-45dd-99e6-b42565045fa1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.31,
        "x": 0.36,
        "y": 0.23
      },
      "kind": "list",
      "text": "AZD5305 PARP1-selective inhibitor; Five abstracts at AACR; Selective PARP1-DNA trapper; More potent and efficacious than first-generation PARP inhibitors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "984a265c-cb68-4b75-b06e-f832d612f919",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.31,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "list",
      "text": "Lynparza adjuvant breast cancer Phase III OlympiaA trial unblinded; IDMC recommended trial move to primary analysis; Anticipated to become new standard of care",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd6a937c-ad3f-4304-a05c-25110f537d0e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.29,
        "x": 0.68,
        "y": 0.23
      },
      "kind": "list",
      "text": "Upcoming Enhertu breast cancer data readouts: H2 2021 DESTINY-Breast03; 2022 DESTINY-Breast02, 04; 2022+ Multiple trials",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0b9eec7-d3b9-4e08-9638-8b8d88c3e209",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Independent Data Monitoring Committee 2. Invasive disease-free survival. 3. Abstract ND05, American Association for Cancer Research, 2021.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9ce89b1-7528-40f7-ad68-500da81e080a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.23,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Breast cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21123294-bd26-4725-9b2a-89710688eb72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.55,
        "x": 0.03,
        "y": 0.11
      },
      "kind": "title",
      "text": "Progressing pipeline across multiple modalities",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f666148-6953-4d81-9812-145bae2d54fc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}